Collegium Pharmaceutical (NASDAQ:COLL) Research Coverage Started at Oppenheimer

Oppenheimer assumed coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a report published on Wednesday, MarketBeat.com reports. The firm issued an outperform rating and a $50.00 price target on the specialty pharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Piper Sandler reissued a “neutral” rating and set a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. Wall Street Zen cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Leerink Partners assumed coverage on Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price on the stock. Finally, Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $48.71.

Collegium Pharmaceutical Trading Down 0.5%

Collegium Pharmaceutical stock opened at $22.53 on Wednesday. The firm has a market cap of $733.58 million, a PE ratio of 18.17, a P/E/G ratio of 0.73 and a beta of 0.72. Collegium Pharmaceutical has a 12 month low of $21.65 and a 12 month high of $50.79. The stock’s 50 day simple moving average is $27.85 and its two-hundred day simple moving average is $32.17. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. During the same period in the previous year, the firm earned $1.68 EPS. The business’s quarterly revenue was up 6.3% on a year-over-year basis. Analysts anticipate that Collegium Pharmaceutical will post 6.19 earnings per share for the current year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Large investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd boosted its stake in shares of Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 427 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 418 shares during the last quarter. Hantz Financial Services Inc. lifted its holdings in Collegium Pharmaceutical by 51.8% in the 4th quarter. Hantz Financial Services Inc. now owns 2,602 shares of the specialty pharmaceutical company’s stock valued at $120,000 after purchasing an additional 888 shares in the last quarter. Assetmark Inc. lifted its holdings in Collegium Pharmaceutical by 9.3% in the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 335 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in Collegium Pharmaceutical by 20.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock worth $167,000 after purchasing an additional 861 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.

Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain.